JP2023027066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023027066A5 JP2023027066A5 JP2022182194A JP2022182194A JP2023027066A5 JP 2023027066 A5 JP2023027066 A5 JP 2023027066A5 JP 2022182194 A JP2022182194 A JP 2022182194A JP 2022182194 A JP2022182194 A JP 2022182194A JP 2023027066 A5 JP2023027066 A5 JP 2023027066A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline
- preparing
- powder
- compound
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MUGXRYIUWFITCP-PGRDOPGGSA-N (1r,2s)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-n-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide Chemical compound CC1=NC(C)=NC=C1OC[C@]1(C=2C=C(F)C=CC=2)[C@H](C(=O)NC=2N=CC(F)=CC=2)C1 MUGXRYIUWFITCP-PGRDOPGGSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 229940123730 Orexin receptor antagonist Drugs 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710648135.2 | 2017-08-01 | ||
| CN201710648135 | 2017-08-01 | ||
| PCT/CN2018/097797 WO2019024845A1 (zh) | 2017-08-01 | 2018-07-31 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
| JP2020504160A JP7179049B2 (ja) | 2017-08-01 | 2018-07-31 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504160A Division JP7179049B2 (ja) | 2017-08-01 | 2018-07-31 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023027066A JP2023027066A (ja) | 2023-03-01 |
| JP2023027066A5 true JP2023027066A5 (https=) | 2023-08-01 |
Family
ID=65233118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504160A Active JP7179049B2 (ja) | 2017-08-01 | 2018-07-31 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
| JP2022182194A Pending JP2023027066A (ja) | 2017-08-01 | 2022-11-15 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504160A Active JP7179049B2 (ja) | 2017-08-01 | 2018-07-31 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10759779B2 (https=) |
| JP (2) | JP7179049B2 (https=) |
| CN (2) | CN110799501B (https=) |
| WO (1) | WO2019024845A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7179049B2 (ja) * | 2017-08-01 | 2022-11-28 | ベルゲン ファーマシューティカル、 エルエルシー | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
| TW202432509A (zh) * | 2019-05-15 | 2024-08-16 | 日商衛材R&D企管股份有限公司 | 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生 |
| WO2020263253A1 (en) * | 2019-06-26 | 2020-12-30 | Moline Margaret | Lemborexant for treating sleep issues |
| CN114502167A (zh) * | 2019-09-13 | 2022-05-13 | 卫材R&D管理有限公司 | 用于治疗失眠的药物组合物 |
| US12534448B2 (en) | 2019-12-11 | 2026-01-27 | Tapi Czech Industries S.R.O | Solid state form of lemborexant |
| US20230103250A1 (en) * | 2020-01-16 | 2023-03-30 | Eisai R&D Management Co., Ltd. | Drug substance of lemborexant and medicinal composition comprising same |
| CN119285556B (zh) * | 2024-12-13 | 2025-02-28 | 四川健林药业有限责任公司 | 莱博雷生中间体的合成纯化方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020157A (en) * | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) * | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| WO2012039371A1 (ja) | 2010-09-22 | 2012-03-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シクロプロパン化合物 |
| JP6147279B2 (ja) | 2012-02-17 | 2017-06-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | オレキシン−２受容体アンタゴニストの合成において有用な方法および化合物 |
| MX376164B (es) * | 2014-10-23 | 2025-03-07 | Eisai R&D Man Co Ltd | Composiciones y metodos para tratar el insomnio. |
| CN107501223A (zh) | 2014-12-15 | 2017-12-22 | 云南省药物研究所 | 灯盏乙素苷元晶型及其制备方法 |
| JP7179049B2 (ja) * | 2017-08-01 | 2022-11-28 | ベルゲン ファーマシューティカル、 エルエルシー | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
-
2018
- 2018-07-31 JP JP2020504160A patent/JP7179049B2/ja active Active
- 2018-07-31 CN CN201880040538.1A patent/CN110799501B/zh active Active
- 2018-07-31 WO PCT/CN2018/097797 patent/WO2019024845A1/zh not_active Ceased
- 2018-07-31 CN CN202211397034.XA patent/CN115710250A/zh active Pending
-
2020
- 2020-01-30 US US16/777,121 patent/US10759779B2/en active Active
-
2022
- 2022-11-15 JP JP2022182194A patent/JP2023027066A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023027066A5 (https=) | ||
| JP2023002516A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| JP2024071370A5 (https=) | ||
| JP2021028338A5 (https=) | ||
| JP2023036708A5 (https=) | ||
| JPWO2022138988A5 (https=) | ||
| JPWO2020245133A5 (https=) | ||
| JP2009520690A5 (https=) | ||
| JP2011506330A5 (https=) | ||
| JP2009535340A5 (https=) | ||
| JP2004526788A5 (https=) | ||
| JP2012516344A5 (https=) | ||
| JP2015145426A5 (https=) | ||
| JP2023109937A5 (https=) | ||
| JP2006249089A5 (https=) | ||
| JP2020528913A5 (https=) | ||
| CN110225781A (zh) | 噻唑衍生物及其应用 | |
| JPWO2021033729A5 (https=) | ||
| JP2020138960A5 (https=) | ||
| JPWO2020051538A5 (https=) | ||
| JP2018516946A5 (https=) | ||
| MX2013010702A (es) | Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen. | |
| JPWO2021150723A5 (https=) | ||
| JPWO2019024845A5 (https=) |